Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M BERGMAN

Showing results (701-710 of 784) with videos related to

Pageof 79
Sort By:
Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
A Tissue Systems Pathology Assay for High-Risk Barrett's EsophagusRebecca J Critchley-Thorne, Lucas C Duits, Jeffrey W Prichard, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 24, 2022
Clinical Relevance of Random Biopsies From the Esophagogastric Junction After Complete Eradication of Barrett's Esophagus is LowCharlotte N Frederiks, Sanne N van Munster, Esther A Nieuwenhuis, et al.
Diabetes Research and Clinical Practice|January 15, 2022
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)Annieke C G van Baar, Jacques Devière, David Hopkins, et al.
Endoscopy|January 31, 2022
Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitalsEsther A Nieuwenhuis, Sanne N van Munster, Wouter L Curvers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
The Prostate|September 23, 2015
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relationSushil K Badrising, Vincent van der Noort, Alfons J M van den Eertwegh, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 10, 2026
Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registryK J M van der Velden, D Bosch, Z Vassilev, et al.
Pageof 79

Showing results (701-710 of 784) with videos related to

Sort By:
Pageof 79
Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
A Tissue Systems Pathology Assay for High-Risk Barrett's EsophagusRebecca J Critchley-Thorne, Lucas C Duits, Jeffrey W Prichard, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 24, 2022
Clinical Relevance of Random Biopsies From the Esophagogastric Junction After Complete Eradication of Barrett's Esophagus is LowCharlotte N Frederiks, Sanne N van Munster, Esther A Nieuwenhuis, et al.
Diabetes Research and Clinical Practice|January 15, 2022
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)Annieke C G van Baar, Jacques Devière, David Hopkins, et al.
Endoscopy|January 31, 2022
Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitalsEsther A Nieuwenhuis, Sanne N van Munster, Wouter L Curvers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
The Prostate|September 23, 2015
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relationSushil K Badrising, Vincent van der Noort, Alfons J M van den Eertwegh, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 10, 2026
Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registryK J M van der Velden, D Bosch, Z Vassilev, et al.
Pageof 79